The combined treatment with novel platinum(II) complex and anti-MUC1 increases apoptotic response in MDA-MB-231 breast cancer cells

Molecular and Cellular Biochemistry

Volumn 408, Issue 1-2, 2015, Pages 103-113

  Gornowicz, Agnieszka ^a   Bielawska, Anna ^a   Czarnomysy, Robert ^a   Gabryel Porowska, Halina ^a   Muszyńska, Anna ^a   Bielawski, Krzysztof ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Anti MUC1; Anticancer drugs; Apoptotic markers; Platinum complexes; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; LIPOCORTIN 5; MONOCLONAL ANTIBODY; MUCIN 1; PLATINUM DERIVATIVE; PROTEIN BAX; MUC1 PROTEIN, HUMAN; PLATINUM COMPLEX;

APOPTOSIS; ARTICLE; BINDING ASSAY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER THERAPY; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOTHERAPY; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; IMMUNOLOGY; MULTIMODALITY CANCER THERAPY; PROCEDURES; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA FRAGMENTATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MUCIN-1; ORGANOPLATINUM COMPOUNDS;

EID: 84941997664     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-015-2486-z     Document Type: Article

References (31)

1. Zhou Y, Rajabi H, Kufe D (2011) Mucin 1 C-terminal subunit oncoprotein is a target for small-molecule inhibitors. Mol Pharmacol 79:886–893. doi:10.1124/mol.110.070797
2. Constantinou PE, Danysh BP, Dharmaraj N, Carson DD (2011) Transmembrane mucins as novel therapeutic targets. Expert Rev Endocrinol Metab 6:835–848. doi:10.1586/eem.11.70
3. Kufe DW (2013) MUC1-C oncoprotein as a target in breast cancer; activation of signaling pathways and therapeutic approaches. Oncogene 32:1073–1081. doi:10.1038/onc.2012.158
4. Horm TM, Schroeder JA (2013) MUC1 and metastatic cancer. Expression, function and therapeutic targeting. Cell Adhes Migr 7:187–198. doi:10.4161/cam.23131
5. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337. doi:10.1158/1078-0432
6. Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S (2013) Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 24:2316–2324. doi:10.1093/annonc/mdt162
7. Siragusa M, Zerili M, Iovino F, Francipane MG, Lombardo Y, Ricci-Vitani L, Di Gesu G, Todero M, De Maria R, Stassi G (2007) MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells. Cancer Res 67:5522–5530. doi:10.1158/0008-5472.CAN-06-4197
8. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C (2009) MUC1 is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer Res Treat 118:113–124. doi:10.1007/s10549-009-0412-3
9. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D (2004) Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 5:163–175. doi:10.1007/s10549-009-0412-3
10. Ahmad R, Alam M, Rajabi H, Kufe D (2012) The MUC1-C oncoprotein binds to the BH3 domain of the pro-apoptotic BAX protein and blocks BAX function. J Biol Chem 287:20866–20875. doi:10.1074/jbc.M112.357293
11. Agata N, Ahmad R, Kawano T, Raina D, Kharbanda S, Kufe D (2008) MUC1 oncoprotein blocks death receptor-mediated apoptosis by inhibiting recruitment of caspase-8. Cancer Res 68:6136–6144. doi:10.1158/0008-5472
12. Powróźnik B, Kubowicz P, Pękala E (2012) Monoclonal antibodies in targeted therapy. Postep Hig Med Dosw 66:663–673
13. Campoli M, Ferris R, Ferrone S, Wang X (2010) Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies. Clin Cancer Res 16:11–20. doi:10.1158/1078-0432
14. Li GN, Wang SP, Xue X, Qu XJ, Liu HP (2013) Monoclonal antibody-related drugs for cancer therapy. Drug Discov Ther 7:178–184. doi:10.5582/ddt.2013.v7.5.178
15. Pućkowska A, Bielawski K, Bielawska A, Midura-Nowaczek K (2004) Aromatic analogues of DNA minor groove binders—synthesis and biological evaluation. Eur J Med Chem 39:99–105. doi:10.1016/j.ejmech.2003.11.005
16. Bielawski K, Bielawska A, Sosnowska K, Miltyk W, Winnicka K, Pałka J (2006) Novel amidine analogue of melphalan as a specific multifunctional inhibitor of growth and metabolism of human breast cancer cells. Biochem Pharmacol 72:320–331. doi:10.1016/j.bcp.2006.04.028
17. Sienkiewicz P, Bielawski K, Bielawska A, Pałka J (2004) Amidine analogue of chlorambucil is a stronger inhibitor of protein and DNA synthesis in breast cancer MCF-7 cells than is the parent drug. Eur J Pharmacol 492:95–101. doi:10.1016/j.ejphar.2004.04.001
18. Bielawska A, Popławska B, Surażyński A, Czarnomysy R, Bielawski K (2010) Cytotoxic efficacy of a novel dinuclear platinum(II) complex in human breast cancer cells. Eur J Pharmacol 643:34–41. doi:10.1016/j.ejphar.2010.06.022
19. Bielawski K, Czarnomysy R, Muszyńska A, Bielawska A, Popławska B (2013) Cytotoxicity and induction of apoptosis of human breast cancer cells by novel platinum(II) complexes. Environ Toxicol Pharmacol 35:254–264. doi:10.1016/j.etap.2012.12.010
20. Gornowicz A, Kałuża Z, Bielawska A, Gabryel-Porowska H, Czarnomysy R, Bielawski K (2014) Cytotoxic efficacy of a novel dinuclear platinum(II) complex used with anti-MUC1 in human breast cancer cells. Mol Cell Biochem 392:161–174. doi:10.1007/s11010-014-2018-2
21. Holliday DL, Speirs V (2011) Choosing the right cell line for breast cancer research. Breast Cancer Res 13:215. doi:10.1186/bcr2889
22. Westermann B (2008) Molecular machinery of mitochondrial fusion and fission. J Biol Chem 283:13501–13505. doi:10.1074/jbc.R800011200
23. Singh SK, Moretta D, Almaguel F, Wall NR, De Leon M, De Leon D (2007) Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 25:363–372. doi:10.1080/08977190801886905
24. Sánchez-Alcázar JA, Ault JG, Khodjakov A, Schneider E (2000) Increased mitochondrial cytochrome c levels and mitochondrial hyperpolarization precede camptothecin-induced apoptosis in Jurkat cells. Cell Death Differ 7:1090–1100
25. Wang L, Chen H, Liu F, Madigan MC, Power CA, Hao J, Patterson KI, Pourgholami MH, O’Brien PM, Perkins AC, Li Y (2011) Monoclonal antibody targeting MUC1 and increasing sensitivity to docetaxel as a novel strategy in treating human epithelial ovarian cancer. Cancer Lett 300:122–133. doi:10.1016/j.canlet.2010.09.013
26. Wang L, Chen H, Pourgholami MH, Beretov J, Hao J, Chao H, Perkins AC, Kaersley JH, Li Y (2011) Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model. PLoS One 6:e24405. doi:10.1371/journal.pone.0024405
27. Mohit E, Hashemi A, Allahyari M (2014) Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Rev Clin Immunol 10:927–961. doi:10.1586/1744666X.2014.916211
28. Raina D, Kharbanda S, Kufe D (2004) The MUC1 onco-protein activates the anti-apoptotic PI3K/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 279:20607–20612. doi:10.1074/jbc.M310538200
29. Wei X, Xu H, Kufe D (2005) Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 7:167–178. doi:10.1016/j.ccr.2005.01.008
30. Raina D, Ahmad R, Kumar S, Ren J, Yoshida K, Kharbanda S, Kufe D (2006) MUC1 oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA damage. EMBO J 25:3774–3783. doi:10.1038/sj.emboj.7601263
31. Uschida Y, Raina D, Kharbanda S, Kufe D (2013) Inhibition of the MUC1-C oncoprotein is synergistic with cytotoxic agents in the treatment of breast cancer cells. Cancer Biol Ther 14:127–134. doi:10.4161/cbt.22634